Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 3/20 | 0.46 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.46 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.44 |
| ▸ | OPRL1 | P41146 | 5/20 | 0.42 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.41 |
| ▸ | NPY1R | P25929 | 2/20 | 0.39 |
| ▸ | NPY2R | P49146 | 2/20 | 0.39 |
| ▸ | NPY4R | P50391 | 2/20 | 0.39 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.39 |
| ▸ | IL23R | Q5VWK5 | 2/20 | 0.39 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.39 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31393356 | 0.96 | OPRM1 (0.43) | OPRM1OPRD1OPRK1OPRL1PRMT1 | |
| SCHEMBL30443571 | 0.92 | OPRM1 (0.46) | OPRM1OPRD1OPRK1OPRL1NPY1R | |
| SCHEMBL29374718 | 0.88 | TFPI (0.44) | OPRM1OPRD1OPRK1PRMT1IL23R | |
| SCHEMBL30006921 | 0.86 | OPRL1 (0.49) | OPRL1PRMT1IL23R | |
| SCHEMBL30966635 | 0.86 | OPRL1 (0.50) | OPRM1OPRD1OPRL1PRMT1NPY1R | |
| SCHEMBL29470904 | 0.86 | TFPI (0.46) | IL23R | |
| SCHEMBL30297059 | 0.86 | IL23R (0.42) | OPRL1NPY1RNPY2RNPY4RNPY5R | |
| SCHEMBL29375236 | 0.85 | TFPI (0.43) | IL23R | |
| SCHEMBL29816322 | 0.85 | NPY4R (0.46) | OPRM1OPRD1OPRK1NPY1RNPY2R | |
| SCHEMBL31236827 | 0.84 | IL23R (0.42) | IL23R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220362381-A1 | REMOTELY TRIGGERED THERAPY | BAMBU VAULT LLC (US) | 2022-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220362381-A1 | REMOTELY TRIGGERED THERAPY | CD47, HSP90AA1, HSF1 | OPRM1 3782/4885OPRD1 4785/4885OPRK1 4178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.